Entriptinib 100 mg Entrectinib capsules 100 mg/capsule, 60 capsules/box

Medication Safety Tips

Use this product according to its instructions, medical advice, and your health needs. Shipping is arranged after payment once the order meets dispatch requirements.

Contraindications

Warnings and Precautions
• Congestive heart failure: In patients with symptoms or known risk factors for congestive heart failure, the left ventricular ejection fraction should be assessed before starting LuciEntre. Monitor the patient for clinical signs and symptoms of congestive heart failure (CHF). For patients with myocarditis, an MRI or cardiac biopsy may be required to make a diagnosis, whether or not the ejection fraction is reduced. For new or worsening congestive heart failure, LuciEntre should be suspended, LVEF re-evaluated and appropriate medical management undertaken. Dose reduction or permanent discontinuation of LuciEntre based on the severity of congestive heart failure or worsening LVEF.
• Central nervous system (CNS) effects: Adverse CNS effects may occur with LuciEntre, including cognitive impairment, mood disorders, dizziness, and sleep disorders. Depending on the severity, discontinue and return to the same or reduced dose after improvement, or permanently discontinue LuciEntre.
• Fractures: LuciEntre increases the risk of fractures. Timely assessment of patients with signs or symptoms of fracture.
• Hepatotoxicity: Hepatic function tests including ALT and AST are monitored every 2 weeks during the first month of treatment, then monthly thereafter and as clinically indicated. Suspend or permanently deactivate LuciEntre based on severity. If paused, resume LuciEntre at the same or reduced dose depending on the severity.
• Hyperuricemia: Serum uric acid levels are regularly assessed before and during treatment with LuciEntre. Monitor the patient for signs and symptoms of hyperuricemia. Start treatment with lower uric acid medication as clinically indicated and discontinue LuciEntre based on signs and symptoms of hyperuricemia. Return to medication at the same or reduced dose depending on the severity and after improvement of the condition.
• Prolonged QT interval: Patients with prolonged QTc interval or at risk of prolonged QTc interval will be monitored. The baseline QT interval and electrolytes are regularly assessed during and during treatment. Suspend and then resume at the same or reduced dose, or permanently discontinue LuciEntre, depending on the severity.
• Visual impairment: In the event of new vision changes or changes in activities that affect daily living, interrupt the medication until the condition improves or stabilizes. Perform ophthalmic assessments as appropriate. When the condition improves or stabilizes, resume at the same or reduced dose.
• Embryo-fetal toxicity: May cause harm to the fetus. Women of childbearing potential are advised to be aware of the potential risks to the fetus and to use effective contraception.

Medication risks

Adverse Reactions
The most common adverse reactions (≥ 20%) are fatigue, constipation, taste disturbance, edema, dizziness, diarrhea, nausea, paresthesia, dyspnea, myalgia, cognitive impairment, weight gain, cough, vomiting, pyrexia, joint pain, and visual impairment